Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or
Drug | Drug Name | Drug Description |
---|
Drug | Drug Name | Target | Type |
---|
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB06769 | Bendamustine | 2 | Completed | 1 |
DB06650 | Ofatumumab | 2 | Completed | 1 |